

PARAQUAT DEFENCE

Notes on a meeting held 01/11/85.

Present:

- | | |
|----------------------------------|--------------------------------|
| A K Stapleton, Herbicides Dept. | D H Brooks, Development Dept. |
| W R T Cottrell, Herbicides Dept. | G M Farrell, Development Dept. |
| P J Bramley, Herbicides Dept. | C A Spinks, Development Dept. |
| L L Smith, CTL | T B Hart, PS & RG |
| R Scott, CTL | G A Willis, PS & RG |
| N G E Geach, FEP | |
| C S Major, Public Affairs | |
| P Slade, Public Affairs | |

1. Current Issues

Circulate to SET/RSM and IFHD for info.

Leads

a. Develop analytical methods

b. Carry out acute toxicity and acute tests

c. Review previous work on level of addition

d. Carry out chronic tests, after c., to determine rate of addition

e. Prove stability in Brazil

In Japan, it was agreed should contain either (ref letters from TBH of April 1986, the possible:

- ACTION
- WED
 - CTL
 - TBH

ICI J
TAL/WED

Must be informed if/when ICI PPD is satisfied on technical feasibility

Paraquat SAC
(see below)

1.2 Rate of addition of emetic

LLS presented data which suggested strongly that higher levels of PP796 (up to 5x) might induce more rapid emesis in man than current levels. The need for rapid emesis was agreed.

Although there were some concerns that such a change might not produce a noticeable change in mortality statistics, it was agreed that further work should be done with urgency:

- a. develop the rationale for the change to a level which could be presented to Registration Authorities
- b. develop a short list of countries/areas where testing could meaningfully be done.
- c. determine the maximum level of emetic that can be achieved in Gramoxone and Preeglox. (This may limit the potential increase in concentration)

ACTION

CTL
subgroup led by GAW

WED

Safening of PQ

COMPANY SECRET

PARAQUAT DEFENCE

Notes on a meeting held 01/11/85.

Present:

A K Stapleton, Herbicides Dept.	D H Brooks, Development Dept.
W R T Cottrell, Herbicides Dept.	G M Farrell, Development Dept.
P J Bramley, Herbicides Dept.	C A Spinks, Development Dept.
L L Smith, CTL	T B Hart, PS & RG
R Scott, CTL	G A Willis, PS & RG
N G E Geach, FEP	
C S Major, Public Affairs	
P Slade, Public Affairs	

1. Current Issues

1.1 Bittering agents

Following a presentation on the current situation in Japan, it was agreed that, subject to technical feasibility, Preeglox should contain either Bitrex (denatonium benzoate) or denatonium saccharide (ref letters from TBH and LLS). In order to meet the introduction date of April 1986, the following work needs to be carried out as soon as possible:

a. develop suitable analytical methods	<u>ACTION</u>
b. carry out acute toxicity and Ames tests	WED
c. review previous work on level of addition	CTL
d. carry out tasting tests, after c., to determine rate of addition	TBH
e. prove stability in Preeglox	ICI J TAL/WED

MAFF be informed if/when ICI PPD is satisfied on technical feasibility

Paraquat SAC
(see below)

1.2 Rate of addition of emetic

LLS presented data which suggested strongly that higher levels of PP796 (up to 5x) might induce more rapid emesis in man than current levels. The need for rapid emesis was agreed.

Although there were some concerns that such a change might not produce a noticeable change in mortality statistics, it was agreed that further work should be done with urgency:

a. develop the rationale for the change to a level which could be presented to Registration Authorities	<u>ACTION</u>
b. develop a short list of countries/areas where testing could meaningfully be done.	CTL subgroup led by GAW
c. determine the maximum level of emetic that can be achieved in Gramoxone and Preeglox. (This may limit the potential increase in concentration)	WED

2. Review of Countries at Risk

It was agreed that the table in the July Exec. Paper should be redrawn as 'risk to the business' since this would cover both risks to registration and risk of restrictions on sales.

ACTION
Dev. Dept.

The following information would be incorporated where appropriate:-

1. Brazil: No change in category, but the extra restrictions have been placed on sales. An alleged death in use and consequent publicity was noted.
2. USA: The EPA's determination that paraquat was a mild onlogen was still being evaluated.
A risk analysis is to be completed before year end. ACTION
CTL
3. Holland: High risk now. But the authorities have agreed to negotiate. Paraquat advertising has been questioned by the Advertising Standards Committee. The likelihood of EEC action, if more than a critical number of countries restricted paraquat, was noted.
4. Malaysia: The risk to registration was judged to have reduced, but some restrictions on sales are likely in the next year.
5. Fiji: High risk now.

It is necessary to obtain Regional ownership for the categorisation and to review definitions. ACTION PJB

The developments in Japan require the development of a question and answer brief v. other authorities. ACTION
GAW/PS/CSM

P Slade had collated a table showing the registration/restrictions/precautions in the top 20 countries: This should be updated six monthly.

ACTION
GAW

3. Review of Technical Work

The circulated project summary sheets were discussed. The following were agreed:

- a. A global list of formulations and additives is needed. ACTION
Paraquat SAC
- b. Work on Acid Blue 3 should commence WED
- c. Treatment methods should be discussed at the next meeting AKS/PJB
- d. A project summary sheet and work on a closed system device should be raised. PJB

4. Future Organisation

PJB had succeeded WRTC as Paraquat Product Manager. Following discussions with the Executive, a Paraquat Strategic Action Committee (SAC) would meet shortly under the chairmanship of AKS; This will supercede the current group.

WRTC

W R T COTTRELL

Circulation:	Those present	A G Potter
	M J Edwards)	R D Morrison
	N C Grabham) WED, Yalding	M J Northcott
	M Thorndycraft)	